Interestingly, anti-CEA-CAR NK-92MI combination therapy with either histone deacetylase-inhibitor sodium butyrate (NaB) or the methylation-inhibitor 5-azacytidine (5-AZA) caused selective killing of HCT116, which imply the clinical importance of epidrugs for prompting CAR-NK cell therapeutic efficacy in human CRC (86). The gene discussed is CEACAM5; the disease is colorectal carcinoma.